Dr. Bazhenova on Sequential Use of Immunotherapy and EGFR TKIs in Lung Cancer

OncLiveTV
11 Jun, 2019 ,

Dr. Bazhenova discusses research that has looked at the use of EGFR TKIs after immunotherapy in patients with EGFR-mutant non–small cell lung cancer. The only data that exist now come from a retrospective, single-center study in which investigators evaluated sequencing immunotherapy and EGFR TKIs. They found that the risk of immune-related adverse events is higher if osimertinib (Tagrisso) is used within 3 months after receiving immunotherapy, explains Bazhenova. That risk decreases if the agent is used 3 to 12 months after receiving immunotherapy.